Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The use of the GATA3 transcription factor in improving Prostate Cancer prognosis and detection.
FY 2009-10
Summary
Prostate cancer is the most common cancer and third leading cause of cancer-related death in Canadian men. More than 95% of the cases are deemed to be curable if detected early, when the cancerous cells are confined to the prostate. Most affected men, however, do not display symptoms at this stage, making detection very difficult. It follows that novel molecular biomarkers for prognosis and detection of prostate cancer are necessary. For the past 2 years, Dr. Maxime Bouchard's research group at McGill University has been investigating the role of a cellular protein, GATA3, in the progression of the disease. They have collected data from cell systems and animal studies supporting a correlation between the loss of GATA3 and tumour progression. The present research proposal aims to expand on these studies with the following specific objectives: (1) characterizing the modifications of GATA3 leading to its downregulation in Prostate Cancer and (2) identifying potential prognosis markers based on the expression profile of GATA3. The loss of GATA3 in prostate cancer cells is most likely due to genetic changes at the level of the DNA sequence, or epigenetic changes, that diminish expression of the gene via secondary mechanisms. Both of these possibilities will be investigated in the project, as identifying these changes is likely to help in the diagnosis of the disease. The loss of GATA3 undoubtedly has an impact on the expression of proteins downstream of it. In a second part, the focus will be to identify proteins that are upregulated when GATA3 is lost, as these will have the potential to be used as novel and better prognosis markers for prostate cancer. The clinical utility of the chosen markers will be evaluated by examining normal and tumour samples from human patients, and by correlating these data with clinical data (such as Gleason score and survival). The CIHR Master's award is crucial in helping achieve these goals.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
200321
Name
Krishnan Vimal
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Not applicable / Specified
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The use of the GATA3 transcription factor in improving Prostate Cancer prognosis and detection.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer/Oncology
Abstract
Prostate cancer is the most common cancer and third leading cause of cancer-related death in Canadian men. More than 95% of the cases are deemed to be curable if detected early, when the cancerous cells are confined to the prostate. Most affected men, however, do not display symptoms at this stage, making detection very difficult. It follows that novel molecular biomarkers for prognosis and detection of prostate cancer are necessary. For the past 2 years, Dr. Maxime Bouchard's research group at McGill University has been investigating the role of a cellular protein, GATA3, in the progression of the disease. They have collected data from cell systems and animal studies supporting a correlation between the loss of GATA3 and tumour progression. The present research proposal aims to expand on these studies with the following specific objectives: (1) characterizing the modifications of GATA3 leading to its downregulation in Prostate Cancer and (2) identifying potential prognosis markers based on the expression profile of GATA3. The loss of GATA3 in prostate cancer cells is most likely due to genetic changes at the level of the DNA sequence, or epigenetic changes, that diminish expression of the gene via secondary mechanisms. Both of these possibilities will be investigated in the project, as identifying these changes is likely to help in the diagnosis of the disease. The loss of GATA3 undoubtedly has an impact on the expression of proteins downstream of it. In a second part, the focus will be to identify proteins that are upregulated when GATA3 is lost, as these will have the potential to be used as novel and better prognosis markers for prostate cancer. The clinical utility of the chosen markers will be evaluated by examining normal and tumour samples from human patients, and by correlating these data with clinical data (such as Gleason score and survival). The CIHR Master's award is crucial in helping achieve these goals.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Krishnan, Vimal
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~